All In Biotech

Drug Trial Radar · NCT05153330

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

55

Actual

Start

Jan 24, 2022

Primary completion

Feb 13, 2025

Study completion May 2, 2025

Sponsor

Lead sponsor
Biomea Fusion Inc.Industry
Sponsor type
Industry
First posted
Dec 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

Conditions

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Mixed-Phenotype Leukemia
  • Cancer
  • Refractory
  • Progression
  • Diffuse Large B Cell Lymphoma
  • Multiple Myeloma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Myeloma, Plasma-Cell
  • Myelomatosis
  • Plasma Cell Myeloma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • BMF-219Drug

    BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4)Time frame: At the end of Cycle 1 (each Cycle is 28 Days in duration)

Locations

41 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California

  • University of Southern California Norris Cancer Center

    Los Angeles, California

  • UCLA Department of Medicine

    Los Angeles, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Stanford Cancer Center

    Stanford, California

  • Mayo Clinic

    Jacksonville, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Blood & Marrow Transplant Group of GA (Northside Hospital)

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Henry Ford Hospital

    Detroit, Michigan

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Gainesville, Virginia

  • Evangelismos General Hospital of Athens

    Athens, Greece

  • Alexandra General Hospital of Athens

    Athens, Greece

  • AOU Ospedali Riuniti Ancona

    Ancona, Italy

  • ASST Papa Giovanni XXIII Hospital Bergamo

    Bergamo, Italy

  • Instituto Clinico Humanitas

    Milan, Italy

  • IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC

    Milan, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Ospedale Santa Maria della Misericordia

    Perugia, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Amsterdam UMC

    Amsterdam, Netherlands

  • UMCG Groningen

    Groningen, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Erasmus University Medical Center Rotterdam

    Rotterdam, Netherlands

  • Hospital General de Albacete

    Albacete, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Institut Catala d'Oncologia

    Barcelona, Spain

  • Hospital San Pedro de Alcántara

    Cáceres, Spain

  • Hospital Universitario de la Princesa

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.